Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma
26 January 2021 07:00 GMT Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma Symbicort Turbuhaler becomes the first dual-combination therapy approved in China for mild, moderate and severe asthma AstraZeneca's Symbicort Turbuhaler (budesonide/formoterol 160/4.5mcg) has been approved in China as an anti-inflammatory reliever to be taken as-needed in response to symptoms to achieve asthma control in patients with mild asthma aged 12 years and older. The approval by the National Medical Products Administration (NMPA) was based on positive results